Combined therapies for lysosomal storage diseases

Current Molecular Medicine

Volumn 15, Issue 8, 2015, Pages 746-771

  Gabig Ciminska M ^a   Jakobkiewicz Banecka J ^a   Malinowska, M ^a   Kloska, A ^a   Piotrowska, E ^a   Chmielarz, I ^a   Moskot, M ^a   Wegrzyn A ^a   Wegrzyn G ^a  

^a UNIVERSITY OF GDA SK   (Poland)

Author keywords

Combined therapies; Enzyme replacement therapy; Gene therapy; Hematopoietic cell transplantation; Lysosomal storage diseases; Small molecular chaperones; Substrate reduction therapy

Indexed keywords

1 DEOXYNOJIRIMYCIN; AGALSIDASE BETA; ALPHA GALACTOSIDASE; AMBROXOL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BORTEZOMIB; CHAPERONE; CURCUMIN; ELIGLUSTAT; ELOSULFASE ALFA; GENISTEIN; GLUCOSYLCERAMIDASE; GLYCOSPHINGOLIPID; IBUPROFEN; IMIGLUCERASE; IMMUNOSUPPRESSIVE AGENT; LARAZOTIDE; LARONIDASE; METHOTREXATE; MIGLUSTAT; RITUXIMAB; ROSIGLITAZONE; SALBUTAMOL; TALIGLUCERASE ALFA; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UBIDECARENONE; VELAGLUCERASE ALFA;

AEROBIC EXERCISE; ARTICLE; BONE MARROW TRANSPLANTATION; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE THERAPY; GLOBOID CELL LEUKODYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 2; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; MUCOLIPIDOSIS TYPE 1; MUCOPOLYSACCHARIDOSIS; MUTATION; NEURONAL CEROID LIPOFUSCINOSIS; NIEMANN PICK DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SANDHOFF DISEASE; TAY SACHS DISEASE; ANIMAL; LYSOSOMAL STORAGE DISEASES; METABOLISM; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; LYSOSOMAL STORAGE DISEASES;

EID: 84945946922     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150921105658     Document Type: Article

References (201)

1. Beck M. Emerging drugs for lysosomal storage diseases. Expert Opin Emerg Drugs 2010; 15(3): 495-507.
2. Lashford LS, Fairbairn LJ, Wraith JE. Lysosomal storage disorders. Gene therapy technologies, applications and regulations: from laboratory to clinic. Chichester: Wiley; 1999.
3. van Gelder CM, Vollebregt AA, Plug I, van der Ploeg AT, Reuser AJ. Treatment options for lysosomal storage disorders: developing insights. Expert Opin Pharmacother 2012; 13(16): 2281-99.
4. Parenti G, Pignata C, Vajro P, Salerno M. New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med 2013; 31(1): 11-20.
5. Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 2014; 39(3): 215-24.
6. Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 2009; 1793(4): 684-96.
7. Bellettato CM, Scarpa M. Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010; 33(4): 347-62.
8. Parkinson-Lawrence EJ, Shandala T, Prodoehl M, Plew R, Borlace GN, Brooks DA. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology (Bethesda) 2010; 25(2): 102-15.
9. Wegrzyn G, Jakobkiewicz-Banecka J, Narajczyk M, et al. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? Med Hypotheses 2010; 75(6): 605-9.
10. Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics 2011; 5(3): 156-69.
11. Schultz ML, Tecedor L, Chang M, Davidson BL. Clarifying lysosomal storage diseases. Trends Neurosci 2011; 34(8): 401-10.
12. Cox TM, Cachon-Gonzalez MB. The cellular pathology of lysosomal diseases. J Pathol 2012; 226(2): 241-54.
13. Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol 2012; 199(5): 723-34.
14. Jakobkiewicz-Banecka J, Gabig-Ciminska M, Banecka- Majkutewicz Z, Banecki B, Wegrzyn A, Wegrzyn G. Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases. Metab Brain Dis 2014; 29(1): 1- 8.
15. Klein AD, Futerman AH. Lysosomal storage disorders: old diseases, present and future challenges. Pediatr Endocrinol Rev 2013; 11 Suppl 1: 59-63.
16. Jardim LB, Villanueva MM, de Souza CF, Netto CB. Clinical aspects of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010; 33(4): 315-29.
17. Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010; 62(1): 33-40.
18. Hawkins-Salsbury JA, Reddy AS, Sands MS. Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts? Hum Mol Genet 2011; 20(R1): R54-60.
19. Jakobkiewicz-Banecka J, Piotrowska E, Gabig-Ciminska M, et al. Substrate reduction therapies for mucopolysaccharidoses. Curr Pharm Biotechnol 2011; 12(11): 1860-5.
20. Banecka-Majkutewicz Z, Jakobkiewicz-Banecka J, Gabig- Ciminska M, Wegrzyn A, Wegrzyn G. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses. Arch Immunol Ther Exp (Warsz) 2012; 60(6): 461-8.
21. Wegrzyn A. Gene expression-targeted isoflavone therapy. IUBMB Life 2012; 64(4): 307-15.
22. Burrow TA, Barnes S, Grabowski GA. Prevalence and management of Gaucher disease. Pediatric Health, Medicine and Therapeutics 2011; 2: 59-73.
23. Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz- 112638) treatment: 2-year results of a phase 2 study. Blood 2010; 116(20): 4095-8.
24. Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J 2006; 273(17): 4082-92.
25. Kornhaber GJ, Tropak MB, Maegawa GH, et al. Isofagomine induced stabilization of glucocerebrosidase. Chembiochem 2008; 9(16): 2643-9.
26. Luan Z, Li L, Higaki K, Nanba E, Suzuki Y, Ohno K. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev 2013; 35(4): 317-22.
27. Zimran A, Altarescu G, Elstein D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis 2013; 50(2): 134-7.
28. Capablo JL, Franco R, de Cabezon AS, Alfonso P, Pocovi M, Giraldo P. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. Epilepsia 2007; 48(7): 1406-8.
29. Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol 2008; 64(5): 514-22.
30. ox-Brinkman J, van Breemen MJ, van Maldegem BT, et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis 2008; 31(6): 745-52.
31. Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007; 110(7): 2296-301.
32. Cox TM, Amato D, Hollak CE, et al. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis 2012; 7: 102.
33. Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 2015; 385(9985): 2355-62.
34. Alfonso P, Pampin S, Estrada J, et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis 2005; 35(2): 268-76.
35. Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J. Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm 2011; 8(6): 2390-7.
36. Shen JS, Edwards NJ, Hong YB, Murray GJ. Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun 2008; 369(4): 1071-5.
37. Therapeutics A. Preclinical Results Exploring the Use of Pharmacological Chaperone AT3375 Alone and in Combination with Recombinant Human Beta-Glucosidase for Gaucher Disease. San Diego, CA, USA 2012.
38. Mu TW, Ong DS, Wang YJ, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008; 134(5): 769-81.
39. Babajani G, Kermode A. Alteration of the proteostasis network of plant cells promotes the post-endoplasmic reticulum trafficking of recombinant mutant (L444P) human beta-glucocerebrosidase. Plant Signal Behav 2014; 9(3): e28714.
40. de la Mata M, Cotan D, Oropesa-Avila M, et al. Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant beta-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease. Sci Rep 2015; 5: 10903.
41. Schiffmann R. Fabry disease. Pharmacol Ther 2009; 122(1): 65-77.
42. Mehta AB. Fabry disease: is there a role for enzyme replacement therapy? J Intern Med 2013; 274(4): 329-30.
43. Marshall J, Ashe KM, Bangari D, et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One 2010; 5(11): e15033.
44. Okumiya T, Ishii S, Takenaka T, et al. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun 1995; 214(3): 1219-24.
45. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999; 5(1): 112-5.
46. Guce AI, Clark NE, Rogich JJ, Garman SC. The molecular basis of pharmacological chaperoning in human alphagalactosidase. Chem Biol 2011; 18(12): 1521-6.
47. Germain DP, Giugliani R, Hughes DA, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis 2012; 7: 91.
48. Flanagan JJ, Rossi B, Tang K, et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alphaglucosidase. Hum Mutat 2009; 30(12): 1683-92.
49. Porto C, Pisani A, Rosa M, et al. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis 2012; 35(3): 513-20.
50. Benjamin ER, Khanna R, Schilling A, et al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 2012; 20(4): 717-26.
51. Ishii S. Pharmacological chaperone therapy for Fabry disease. Proc Jpn Acad Ser B Phys Biol Sci 2012; 88(1): 18- 30.
52. Bichet DG, Warnock DG, Holida M, Goker-Alpan O, Nicholls K, Thomas M, Shankar S, Eyskens F, Johnson FK, Sitaraman S, Mudd PN, Jr., Flanagan J, Khanna R, Valenzano KJ, Lockhart DJ, Boudes P, editor. A Phase 2a Study to Investigate the Effect of a Single Dose of Migalastat HCl on Active Agalsidase Activity in Fabry Patients Receiving Enzyme Replacement Therapy The World Symposium for Lysosomal Disorders Annual Meeting (LDN WORLD) 2013; Orlando, FL, USA.
53. Lukas J, Pockrandt AM, Seemann S, et al. Enzyme enhancers for the treatment of fabry and pompe disease. Mol Ther 2015; 23(3): 456-64.
54. Mignani R, Feriozzi S, Schaefer RM, et al. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol 2010; 5(2): 379- 85.
55. Cybulla M, Kurschat C, West M, et al. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J Nephrol 2013; 26(4): 645-51.
56. Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 2011; 13(8): 729-36.
57. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Crossreactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010; 99(1): 26-33.
58. Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, Kishnani PS. beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 2012; 105(2): 221-7.
59. Raben N, Wong A, Ralston E, Myerowitz R. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 2012; 160C(1): 13-21.
60. Maga JA, Zhou J, Kambampati R, et al. Glycosylationindependent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice. J Biol Chem 2013; 288(3): 1428-38.
61. Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 2009; 17(6): 954-63.
62. Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, Reuser AJ. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab 2007; 90(1): 49-57.
63. Parenti G, Zuppaldi A, Gabriela Pittis M, et al. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther 2007; 15(3): 508-14.
64. Porto C, Ferrara MC, Meli M, et al. Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther 2012; 20(12): 2201- 11.
65. Byrne BJ, Falk DJ, Pacak CA, et al. Pompe disease gene therapy. Hum Mol Genet 2011; 20(R1): R61-8.
66. Parenti G, Fecarotta S, la Marca G, et al. A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther 2014; 22(11): 2004-12.
67. Xiao J, Westbroek W, Motabar O, et al. Discovery of a novel noniminosugar acid alpha glucosidase chaperone series. J Med Chem 2012; 55(17): 7546-59.
68. Khanna R, Flanagan JJ, Feng J, et al. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One 2012; 7(7): e40776.
69. Khanna R, Xu S, Pellegrino L, et al. The co-formulation of pharmacological chaperone AT2220 with recombinant human acid alpha-glucosidase improves enzyme uptake and glycogen reduction in a mouse model of Pompe disease. Neuromuscular Disord 2013; 23(9-10): 828-9.
70. Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 2008; 152(1): 138-46.
71. Moran E, Carbone F, Augusti V, Patrone F, Ballestrero A, Nencioni A. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol 2012; 49(3): 270-6.
72. Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 2013; 15(2): 123-31.
73. Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012; 14(1): 135-42.
74. Cousens LP, Mingozzi F, van der Marel S, et al. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother 2012; 8(10): 1459-64.
75. Wraith JE. Mucopolysaccharidoses and mucolipidoses. Handb Clin Neurol 2013; 113: 1723-9.
76. Nilsson MI, Samjoo IA, Hettinga BP, et al. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab 2012; 107(3): 469-79.
77. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 Suppl 5: v4-12.
78. Ortolano S, Vieitez I, Navarro C, Spuch C. Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocr Metab Immune Drug Discov 2014; 8(1): 9-25.
79. Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 Suppl 5: v49-59.
80. Sands MS, Vogler C, Torrey A, et al. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Invest 1997; 99(7): 1596-605.
81. Valayannopoulos V, de Blic J, Mahlaoui N, et al. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation. Pediatrics 2010; 126(5): e1242-7.
82. Akiyama K, Shimada Y, Higuchi T, et al. Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice. Mol Genet Metab 2014; 111(2): 139-46.
83. Grewal SS, Wynn R, Abdenur JE, et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 2005; 7(2): 143-6.
84. Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 2006; 38(1): 17- 21.
85. Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr 2013; 162(2): 375-80 e1.
86. Tolar J, Grewal SS, Bjoraker KJ, et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant 2008; 41(6): 531-5.
87. Bijarnia S, Shaw P, Vimpani A, et al. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome. J Paediatr Child Health 2009; 45(7-8): 469- 72.
88. Wynn RF, Mercer J, Page J, Carr TF, Jones S, Wraith JE. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr 2009; 154(1): 135-9.
89. de Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 2011; 6: 55.
90. Saif MA, Bigger BW, Brookes KE, et al. Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy. Haematologica 2012; 97(9): 1320-8.
91. Sillence D, Waters K, Donaldson S, Shaw PJ, Ellaway C. Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI. JIMD Rep 2012; 2: 103-6.
92. Lamanna WC, Lawrence R, Sarrazin S, et al. A genetic model of substrate reduction therapy for mucopolysaccharidosis. J Biol Chem 2012; 287(43): 36283- 90.
93. Moskot M, Montefusco S, Jakobkiewicz-Banecka J, et al. The phytoestrogen genistein modulates lysosomal metabolism and Transcription Factor EB (TFEB) activation. J Biol Chem 2014; 289(24): 17054-69.
94. Narajczyk M, Moskot M, Konieczna A. Quantitative estimation of lysosomal storage in mucopolysaccharidoses by electron microscopy analysis. Acta Biochim Pol 2012; 59(4): 693-6.
95. Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 2004; 338(3): 453-62.
96. Eliyahu E, Wolfson T, Ge Y, Jepsen KJ, Schuchman EH, Simonaro CM. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One 2011; 6(8): e22447.
97. Schuchman EH, Ge Y, Lai A, et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One 2013; 8(1): e54459.
98. Birkenmeier EH. Correction of murine mucopolysaccharidosis type VII (MPS VII) by bone marrow transplantation and gene transfer therapy. Hum Gene Ther 1991; 2(2): 113.
99. Heldermon CD, Ohlemiller KK, Herzog ED, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAVmediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther 2010; 18(5): 873-80.
100. Hemsley KM, Luck AJ, Crawley AC, et al. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci 2009; 29(6): 1197-214.
101. Osborn MJ, McElmurry RT, Lees CJ, et al. Minicircle DNAbased gene therapy coupled with immune modulation permits long-term expression of alpha-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 2011; 19(3): 450-60.
102. Heldermon CD, Qin EY, Ohlemiller KK, et al. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice. Gene Ther 2013; 20(9): 913-21.
103. Scriver CR. The metabolic and molecular bases of inherited disease. 7th ed. ed. New York; London: McGraw-Hill, Health Professions Division; 1995.
104. Altmann SW, Davis HR, Jr., Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303(5661): 1201-4.
105. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I. Cyclindependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am J Pathol 2004; 165(3): 843-53.
106. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 2001; 11(16): 1283-7.
107. Lachmann RH, te Vruchte D, Lloyd-Evans E, et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann- Pick disease type C. Neurobiol Dis 2004; 16(3): 654-8.
108. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007; 6(9): 765- 72.
109. Wraith JE, Vecchio D, Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: longterm data from a clinical trial. Mol Genet Metab 2010; 99(4): 351-7.
110. Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 2004; 10(7): 704-11.
111. Davidson CD, Ali NF, Micsenyi MC, et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 2009; 4(9): e6951.
112. Hovakimyan M, Petersen J, Maass F, et al. Corneal alterations during combined therapy with cyclodextrin/allopregnanolone and miglustat in a knock-out mouse model of NPC1 disease. PLoS One 2011; 6(12): e28418.
113. Hovakimyan M, Maass F, Petersen J, et al. Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice. Neuroscience 2013; 252: 201-11.
114. Williams IM, Wallom KL, Smith DA, Al Eisa N, Smith C, Platt FM. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice. Neurobiol Dis 2014; 67: 9-17.
115. Bascunan-Castillo EC, Erickson RP, Howison CM, et al. Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. J Appl Genet 2004; 45(4): 461-7.
116. Bu J, Ashe KM, Bringas J, et al. Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther 2012; 20(10): 1893-901.
117. Jin HK, Schuchman EH. Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann- Pick disease. Mol Ther 2003; 8(6): 876-85.
118. Passini MA, Bu J, Fidler JA, et al. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc Natl Acad Sci U S A 2007; 104(22): 9505-10.
119. Jeyakumar M, Butters TD, Dwek RA, Platt FM. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol 2002; 28(5): 343- 57.
120. Abe A, Inokuchi J, Jimbo M, et al. Improved inhibitors of glucosylceramide synthase. J Biochem 1992; 111(2): 191-6.
121. Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 2005; 15(10): 43R-52R.
122. Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 1999; 96(11): 6388-93.
123. Norflus F, Tifft CJ, McDonald MP, et al. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest 1998; 101(9): 1881-8.
124. Jeyakumar M, Norflus F, Tifft CJ, et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 2001; 97(1): 327-9.
125. Jeyakumar M, Smith DA, Williams IM, et al. NSAIDs increase survival in the Sandhoff disease mouse: synergy with Nbutyldeoxynojirimycin. Ann Neurol 2004; 56(5): 642-9.
126. Denny CA, Kasperzyk JL, Gorham KN, Bronson RT, Seyfried TN. Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice. J Neurosci Res 2006; 83(6): 1028-38.
127. Denny CA, Heinecke KA, Kim YP, et al. Restricted ketogenic diet enhances the therapeutic action of Nbutyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. J Neurochem 2010; 113(6): 1525-35.
128. Villamizar-Schiller IT, Pabon LA, Hufnagel SB, et al. Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease. Eur J Med Genet 2015; 58(3): 180-3.
129. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 2004; 279(14): 13478-87.
130. Suzuki K. Globoid cell leukodystrophy (Krabbe's disease): update. J Child Neurol 2003; 18(9): 595-603.
131. Miranda CO, Brites P, Mendes Sousa M, Teixeira CA. Advances and pitfalls of cell therapy in metabolic leukodystrophies. Cell Transplant 2013; 22(2): 189-204.
132. Krivit W, Shapiro EG, Peters C, et al. Hematopoietic stemcell transplantation in globoid-cell leukodystrophy. N Engl J Med 1998; 338(16): 1119-26.
133. Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352(20): 2069-81.
134. Suzuki K. The twitcher mouse. A model of human globoid cell leukodystrophy (krabbe's disease). Am J Pathol 1983; 111(3): 394-7.
135. Strazza M, Luddi A, Carbone M, Rafi MA, Costantino- Ceccarini E, Wenger DA. Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Mol Genet Metab 2009; 97(1): 27-34.
136. Taylor RM, Lee JP, Palacino JJ, et al. Intrinsic resistance of neural stem cells to toxic metabolites may make them well suited for cell non-autonomous disorders: evidence from a mouse model of Krabbe leukodystrophy. J Neurochem 2006; 97(6): 1585-99.
137. Lee WC, Courtenay A, Troendle FJ, et al. Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J 2005; 19(11): 1549-51.
138. Lee WC, Tsoi YK, Troendle FJ, et al. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J 2007; 21(10): 2520-7.
139. Lattanzi A, Salvagno C, Maderna C, et al. Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy. Hum Mol Genet 2014; 23(12): 3250-68.
140. LeVine SM, Pedchenko TV, Bronshteyn IG, Pinson DM. Lcycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice). J Neurosci Res 2000; 60(2): 231-6.
141. Lee WC, Kang D, Causevic E, Herdt AR, Eckman EA, Eckman CB. Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones. J Neurosci 2010; 30(16): 5489-97.
142. Luzi P, Abraham RM, Rafi MA, Curtis M, Hooper DC, Wenger DA. Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res 2009; 1300: 146-58.
143. Berardi AS, Pannuzzo G, Graziano A, Costantino-Ceccarini E, Piomboni P, Luddi A. Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients. Mol Genet Metab 2014; 112(4): 294-301.
144. Hill CH, Viuff AH, Spratley SJ, et al. Azasugar inhibitors as pharmacological chaperones for Krabbe disease. Chem Sci 2015; 6(5): 3075-86.
145. Qin EY, Hawkins-Salsbury JA, Jiang X, et al. Bone marrow transplantation increases efficacy of central nervous systemdirected enzyme replacement therapy in the murine model of globoid cell leukodystrophy. Mol Genet Metab 2012; 107(1- 2): 186-96.
146. Lin D, Donsante A, Macauley S, Levy B, Vogler C, Sands MS. Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy. Mol Ther 2007; 15(1): 44-52.
147. Reddy AS, Kim JH, Hawkins-Salsbury JA, et al. Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy. J Neurosci 2011; 31(27): 9945-57.
148. Galbiati F, Givogri MI, Cantuti L, et al. Combined hematopoietic and lentiviral gene-transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease. J Neurosci Res 2009; 87(8): 1748-59.
149. Hawkins-Salsbury JA, Shea L, Jiang X, et al. Mechanismbased combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. J Neurosci 2015; 35(16): 6495-505.
150. Biswas S, LeVine SM. Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy. Pediatr Res 2002; 51(1): 40-7.
151. Hawkins-Salsbury JA, Qin EY, Reddy AS, Vogler CA, Sands MS. Oxidative stress as a therapeutic target in globoid cell leukodystrophy. Exp Neurol 2012; 237(2): 444-52.
152. Pannuzzo G, Cardile V, Costantino-Ceccarini E, Alvares E, Mazzone D, Perciavalle V. A galactose-free diet enriched in soy isoflavones and antioxidants results in delayed onset of symptoms of Krabbe disease in twitcher mice. Mol Genet Metab 2010; 100(3): 234-40.
153. Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr Suppl 2008; 97(457): 15-21.
154. Krivit W, Shapiro E, Kennedy W, et al. Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322(1): 28-32.
155. Bredius RG, Laan LA, Lankester AC, et al. Early marrow transplantation in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does not halt disease progression. Bone Marrow Transplant 2007; 39(5): 309-10.
156. Solders M, Martin DA, Andersson C, et al. Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. Bone Marrow Transplant 2014; 49(8): 1046- 51.
157. Martin HR, Poe MD, Provenzale JM, Kurtzberg J, Mendizabal A, Escolar ML. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. Biol Blood Marrow Transplant 2013; 19(4): 616-24.
158. Patil SA, Maegawa GH. Developing therapeutic approaches for metachromatic leukodystrophy. Drug Des Devel Ther 2013; 7: 729-45.
159. Okamoto Y, Nagatoshi Y, Kosaka Y, et al. Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatr Transplant 2014; 18(3): 294-301.
160. Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol Bioeng 2013; 110(5): 1456-65.
161. Bockenhoff A, Cramer S, Wolte P, et al. Comparison of five Peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase a. J Neurosci 2014; 34(9): 3122-9.
162. Assadi M, Wang DJ, Anderson K, Carran M, Bilaniuk L, Leone P. Vitamin k antagonist warfarin for palliative treatment of metachromatic leukodystrophy, a compassionate study of four subjects. J Cent Nerv Syst Dis 2012; 4: 73-9.
163. Geng H, Whiteley G, Ribbens J, et al. Novel patient cellbased HTS assay for identification of small molecules for a lysosomal storage disease. PLoS One 2011; 6(12): e29504.
164. Miyake N, Miyake K, Asakawa N, Yamamoto M, Shimada T. Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector. Gene Ther 2014; 21(4): 427-33.
165. Rosenberg JB, Sondhi D, Rubin DG, et al. Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Hum Gene Ther Clin Dev 2014; 25(3): 164-77.
166. Zerah M, Piguet F, Colle MA, et al. Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Hum Gene Ther Clin Dev 2015; 26(2): 113-24.
167. Doerr J, Bockenhoff A, Ewald B, et al. Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy. Mol Ther 2015; 23(9): 1519-31.
168. Warrier V, Vieira M, Mole SE. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta 2013; 1832(11): 1827-30.
169. Anderson GW, Goebel HH, Simonati A. Human pathology in NCL. Biochim Biophys Acta 2013; 1832(11): 1807-26.
170. Xu S, Wang L, El-Banna M, Sohar I, Sleat DE, Lobel P. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2011; 19(10): 1842-8.
171. Lu JY, Nelvagal HR, Wang L, Birnbaum SG, Cooper JD, Hofmann SL. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2015; 116(1-2): 98-105.
172. Vuillemenot BR, Katz ML, Coates JR, et al. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2011; 104(3): 325-37.
173. Katz ML, Coates JR, Sibigtroth CM, et al. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J Neurosci Res 2014; 92(11): 1591-8.
174. Whiting RE, Narfstrom K, Yao G, et al. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Exp Eye Res 2014; 125: 164-72.
175. Vuillemenot BR, Kennedy D, Cooper JD, et al. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Mol Genet Metab 2015; 114(2): 281-93.
176. Souweidane MM, Fraser JF, Arkin LM, et al. Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. J Neurosurg Pediatr 2010; 6(2): 115-22.
177. Pike LS, Tannous BA, Deliolanis NC, et al. Imaging gene delivery in a mouse model of congenital neuronal ceroid lipofuscinosis. Gene Ther 2011; 18(12): 1173-8.
178. Hughes SM, Hope KM, Xu JB, Mitchell NL, Palmer DN. Inhibition of storage pathology in prenatal CLN5-deficient sheep neural cultures by lentiviral gene therapy. Neurobiol Dis 2014; 62: 543-50.
179. Sondhi D, Scott EC, Chen A, et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Hum Gene Ther 2014; 25(3): 223-39.
180. Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr 2013; 11(6): 643- 52.
181. Haltia M. The neuronal ceroid-lipofuscinoses: from past to present. Biochim Biophys Acta 2006; 1762(10): 850-6.
182. Mirza M, Volz C, Karlstetter M, et al. Progressive retinal degeneration and glial activation in the CLN6 (nclf) mouse model of neuronal ceroid lipofuscinosis: a beneficial effect of DHA and curcumin supplementation. PLoS One 2013; 8(10): e75963.
183. Drack AV, Mullins RF, Pfeifer WL, Augustine EF, Stasheff SF, Hong SD. Immunosuppressive Treatment for Retinal Degeneration in Juvenile Neuronal Ceroid Lipofuscinosis (Juvenile Batten Disease). Ophthalmic Genet 2015: 1-6. [Epub ahead of print]; DOI: 10.3109/13816810.2014.886271.
184. Zhang Z, Butler JD, Levin SW, Wisniewski KE, Brooks SS, Mukherjee AB. Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood. Nat Med 2001; 7(4): 478-84.
185. Lu JY, Hofmann SL. Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: implications for treatment of infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis 2006; 29(1): 119-26.
186. Gavin M, Wen GY, Messing J, et al. Substrate Reduction Therapy in Four Patients with Milder CLN1 Mutations and Juvenile-Onset Batten Disease Using Cysteamine Bitartrate. JIMD Rep 2013; 11: 87-92.
187. Levin SW, Baker EH, Zein WM, et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol 2014; 13(8): 777-87.
188. Ghosh A, Corbett GT, Gonzalez FJ, Pahan K. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor alpha: implications for late infantile Batten disease therapy. J Biol Chem 2012; 287(46): 38922-35.
189. Lane SC, Jolly RD, Schmechel DE, Alroy J, Boustany RM. Apoptosis as the mechanism of neurodegeneration in Batten's disease. J Neurochem 1996; 67(2): 677-83.
190. Dhar S, Bitting RL, Rylova SN, et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 2002; 51(4): 448-66.
191. Cialone J, Augustine EF, Newhouse N, et al. Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data. J Inherit Metab Dis 2011; 34(5): 1075-81.
192. Yoon DH, Kwon OY, Mang JY, et al. Protective potential of resveratrol against oxidative stress and apoptosis in Batten disease lymphoblast cells. Biochem Biophys Res Commun 2011; 414(1): 49-52.
193. Huhtala T, Rytkonen J, Jalanko A, et al. Native and Complexed IGF-1: Biodistribution and Pharmacokinetics in Infantile Neuronal Ceroid Lipofuscinosis. J Drug Deliv 2012; 2012: 626417.
194. Macauley SL, Roberts MS, Wong AM, et al. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann Neurol 2012; 71(6): 797- 804.
195. Hu W, Ralay Ranaivo H, Roy SM, et al. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett 2007; 17(2): 414-8.
196. Somera-Molina KC, Robin B, Somera CA, et al. Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia 2007; 48(9): 1785-800.
197. Karpus WJ, Reynolds N, Behanna HA, Van Eldik LJ, Watterson DM. Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. J Neuroimmunol 2008; 203(1): 73-8.
198. Macauley SL, Wong AM, Shyng C, et al. An antineuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci 2014; 34(39): 13077-82.
199. Meng Y, Sohar I, Sleat DE, et al. Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a Peptide that mediates delivery to the brain. Mol Ther 2014; 22(3): 547-53.
200. Roberts MS, Macauley SL, Wong AM, et al. Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis 2012; 35(5): 847-57.
201. O'Leary EM, Igdoura SA. The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis. Mol Genet Metab 2012; 107(1-2): 173-85.